VivoSeq
Other

EGFR-Mutated Locally Advanced or Metastatic NSCLC

4

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

EGFR-mutated Locally Advanced or Metastatic NSCLC is an early-stage landscape with 4 programs across 4 companies. The most active players are CSPC Megalith Biopharmaceutical Co.,Ltd., Gynecologic Oncology Group, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

CSPC Megalith Biopharmaceutical Co.,Ltd.

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3A

Avyxa

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized, Open-label, Multi-center, Phase III Clinical Study Comparing SYS6010 With Platinum-based Chemotherapy in the Treatment of EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of EGFR TKI Treatment
Recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT06927986·380 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)